Chloroquine inhibits MGC803 gastric cancer cell migration via the Toll-like receptor 9/nuclear factor kappa B signaling pathway

Molecular Medicine Reports

Volumn 11, Issue 2, 2015, Pages 1366-1371

  Zhang, Yanli ^a   Li, Yunhong ^a   Li, Yalan ^a   Li, Rui ^a   Ma, Yajun ^a   Wang, Hao ^a   Wang, Yin ^a  

^a NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Cell migration; Chloroquine; Gastric cancer; Nuclear factor KB p65; Toll like receptor 9

Indexed keywords

ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; CHLOROQUINE; CYCLOOXYGENASE 2; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRILYSIN; MESSENGER RNA; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR RELA;

ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE;

ANTIMALARIALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHLOROQUINE; CYCLOOXYGENASE 2; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; NF-KAPPA B; RNA, MESSENGER; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOLL-LIKE RECEPTOR 9; TRANSCRIPTION FACTOR RELA;

EID: 84916197147     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2839     Document Type: Article

References (31)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 127: 2893-2917, 2010.
2. Taghizadeh-Kermani A, Yahouiyan SZ, AliAkbarian M and Seilanian Toussi M: Prognostic significance of metastatic lymph node ratio in patients with gastric cancer: an evaluation in North-East of Iran. Iran J Cancer Prev 7: 73-79, 2014.
3. D'Angelo G, Di Rienzo T and Ojetti V: Microarray analysis in gastric cancer: A review. World J Gastroenterol 20: 11972-11976, 2014.
4. Aderem A and Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 406: 782-787, 2000.
5. Takeda K and Akira S: Toll-like receptors in innate immunity. Int Immunol 17: 1-14, 2005.
6. Oldenburg M, Krger A, Ferstl R, Kaufmann A, Nees G, Sigmund A, et al: TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 337: 1111-1115, 2012.
7. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW and Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 4: 437-447, 2006.
8. Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler wW, et al: Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci 101: 1059-1066, 2010.
9. Schmausser B, Andrulis M, Endrich S, Lee SK, Josenhans C, Mller-Hermelink HK, et al: Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol 136: 521-526, 2004.
10. Schmausser B, Andrulis M, Endrich S, Mller-Hermelink HK and Eck M: Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 295: 179-185, 2005.
11. Wang X, Xue L, Yang Y, Xu L and Zhang G: TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. PLoS One 8: e65731, 2013.
12. Wagner H: The immunobiology of the TLR9 subfamily. Trends Immunol 25: 381-386, 2004.
13. Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, et al: Identification of the IGF1/PI3K/NFkB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer 13: 549, 2013.
14. Zhan Z, Xie X, Cao H, Zhou X, Zhang XD, Fan H, et al: Autophagy facilitates TLR4-and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination. Autophagy 10: 257-268, 2013.
15. Ma YJ, Cui L, Zhang YL and Li XP: Correlations of TLR9 to clinicopathologic features of gastric cancer. J Ningxia Med Univ 34: 126-128, 2012.
16. Romero-Calvo I, Ocon B, Martnez-Moya P, Surez MD, Zarzuelo A, Martnez-Augustin O and de Medina FS: Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem 401: 318-320, 2010.
17. Li MZ, Deng L, Wang JJ, Xiao LB, Wu WH, Yang SB and Li WF: Surgical outcomes and prognostic factors of T4 gastric cancer patients without distant metastasis. PLoS One 9:e107061, 2014.
18. Wang JQ, Jeelall YS, Ferguson LL and Horikawa K: Toll-like receptors and cancer: MYD88 mutation and inflammation. Front Immunol 5: 367-377, 2014.
19. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW and Selander KS: Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 67: 774-781, 2007.
20. Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, Zhou Y, Zhou H and Wen Z: Tlr9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res 15: 623-630, 2009.
21. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709-760, 2002.
22. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5: 190-198, 2004.
23. Maeda S: NF-?B, JNK, and TLR signaling pathways in hepatocarcinogenesis. Gastroenterol Res Pract: 367694, 2010.
24. Kakiuchi Y, Tsuji S, Tsujii M, Murata H, Kawai N and Yasumaru M, et al: Cyclooxygenase-2 activity altered the cell-surface ca-rbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 62: 1567-1572, 2002.
25. Chen R, Alvero AB, Silasi DA, Steffensen KD and Mor G: Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells. Oncogene 27: 225-233, 2008.
26. Jezierska A and Motyl T: Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 15: RA32-RA40, 2009.
27. Sims JD, McCready J and Jay DG: Extracellular heat shock protein (Hsp)70 and Hsp90? assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One 6: e18848, 2011.
28. Okayama H, Kumamoto K, Saitou K, Hayase S, Kofunato Y, Sato Y, et al: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep 22: 745-755, 2009.
29. Yeh YC, Sheu BS, Cheng HC, Wang YL, Yang HB and Wu JJ: Elevated serum matrix metalloproteinase-3 and-7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig Dis Sci 55: 1649-1657, 2010.
30. Sugie S, Tsukino H, Mukai S, Akioka T, Shibata N, Nagano M and Kamoto T: Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese men. Tumour Biol 35: 2717-2721, 2014.
31. Lu J, Li XF, Kong LX, Ma L, Liao SH and Jiang CY: Expression and significance of cyclooxygenase-2 mRNA in benign and malignant ascites. World J Gastroenterol 19: 6883-6887, 2013.